AzTrials
AzTrials

Rheumatoid ArthritisPhase 4NCT01313208

Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)

A Phase 4 study testing etanercept and DMARD Therapy in people with Rheumatoid Arthritis, run by Amgen at 47 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA). Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
etanercept and DMARD Therapy
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
210 participants
Where
47 sitesin 2 countries
Study dates
Mar 2011to May 2013
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female ≥18 and ≤80 years of age at time of screening
  • Diagnosed with rheumatoid arthritis as determined by meeting 1987 American College of Rheumatology (ACR) classification criteria and has had rheumatoid arthritis for at least 6 months
  • Moderate rheumatoid arthritis during screening, as defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) > 3.2 and ≤ 5.1
  • Active rheumatoid arthritis defined as ≥ 3 swollen joints (out of 28 joints examined) and ≥ 3 tender/painful joints (out of 28 joints examined) at screening and baseline. (A full 66/68 count joint count will be performed at baseline, but only joints in the 28-count joint count will be considered for eligibility. The 28-joint count consists of the finger joints excluding the distal interphalangeal joints, the wrists, elbows, shoulders, and knees)
  • Must be currently taking a DMARD such as methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine

Who cannot join

  • Prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening
  • Class IV rheumatoid arthritis according to ACR revised response criteria
  • Any active infection (including chronic or localized infections) for which anti-infectives were indicated within 28 days prior to first investigational product dose
  • Previously used more than one experimental biologic DMARD. Patient with prior use of no more than one experimental biologic is permitted if the subject received no more than 8 weeks of treatment. The use of the experimental biologic must not have occurred within 2 months of the first dose of investigational product
  • Previously used more than one commercially available biologic DMARD. Subject with prior use of no more than one commercially available biologic is permitted if the patient received no more than 8 weeks of treatment and did not discontinue because of lack of effect. The use of the biologic must not have occurred within 2 months of the first dose of investigational product. Acceptable prior use of biologics include the following examples:
  • No more than 4 injections of adalimumab
Show all 10Show fewer
  • No more than 8 (50 mg) injections of etanercept
  • No more than 2 infusions of infliximab
  • No more than 2 infusions of abatacept
  • Additional inclusion (exclusion) criteria may apply

Trial locations and contacts

47 sites in 2 countries.

47 sites in 2 countries

United States38 sites
  • Research Site

    Akron, Ohio, 44311

  • Research Site

    Atlanta, Georgia, 30342

  • Research Site

    Birmingham, Alabama, 35205

  • Research Site

    Bismarck, North Dakota, 58501

  • Research Site

    Chesapeake, Virginia, 23320

  • Research Site

    Dallas, Texas, 75231

  • Research Site

    Denver, Colorado, 80230

  • Research Site

    Encino, California, 91436

  • Research Site

    Erie, Pennsylvania, 16508

  • Research Site

    Frederick, Maryland, 21702

  • Research Site

    Greer, South Carolina, 29650

  • Research Site

    Hemet, California, 92543

  • Research Site

    Inglewood, California, 90301

  • Research Site

    Jacksonville, Florida, 32209

  • Research Site

    La Jolla, California, 92037

  • Research Site

    Lansing, Michigan, 48910

  • Research Site

    Lexington, Kentucky, 40504

  • Research Site

    Mayfield Village, Ohio, 44143

  • Research Site

    Meridian, Idaho, 83642

  • Research Site

    Murrieta, California, 92563

  • Research Site

    Ocala, Florida, 34474

  • Research Site

    Oklahoma City, Oklahoma, 73103

  • Research Site

    Oklahoma City, Oklahoma, 73109

  • Research Site

    Peoria, Arizona, 85381

  • Research Site

    Portland, Oregon, 97239

  • Research Site

    Saint Clair Shores, Michigan, 48081

  • Research Site

    San Antonio, Texas, 78232

  • Research Site

    Santa Maria, California, 93454

  • Research Site

    Sarasota, Florida, 34239

  • Research Site

    Scottsdale, Arizona, 85258

  • Research Site

    Seattle, Washington, 98133

  • Research Site

    Sebring, Florida, 33870

  • Research Site

    Springfield, Illinois, 62704

  • Research Site

    Tampa, Florida, 33613

  • Research Site

    Tuscaloosa, Alabama, 35406

  • Research Site

    Tustin, California, 92780

  • Research Site

    Upland, California, 91786

  • Research Site

    Victorville, California, 92395

Other trials in United States

Canada9 sites
  • Research Site

    Burlington, Ontario, L7R 1E2

  • Research Site

    Laval, Quebec, H7T 2P5

  • Research Site

    Montreal, Quebec, H1T 2M4

  • Research Site

    Montreal, Quebec, H2L 1S6

  • Research Site

    Montreal, Quebec, H3Z 2Z3

  • Research Site

    Québec, Quebec, G1V 3M7

  • Research Site

    Saint-Eustache, Quebec, J7P 4J2

  • Research Site

    St. John's, Newfoundland and Labrador, A1C 5B8

  • Research Site

    Winnipeg, Manitoba, R3A 1M3

Other trials in Canada

About this study

Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Subjects With Moderately Active Rheumatoid Arthritis Despite DMARD Therapy

This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).

Being tested
etanercept, Placebo, DMARD Therapy
Keywords
RA, Enbrel, DMARD, Joint Count, Rheumatoid Arthritis, Etanercept, disease modifying anti-rheumatic drug
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • etanerceptDrug

    Also called Enbrel

    Administered by subcutaneous injection once weekly.

  • PlaceboDrug

    Placebo subcutaneous injection

  • DMARD TherapyDrug

    Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine

Study groups in NCT01313208
Study groupRoleWhat they receive
PlaceboPlacebo comparatorParticipants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks. All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period.
Receives: Drug: etanercept; Drug: Placebo; Drug: DMARD Therapy
EtanerceptExperimentalParticipants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks. All participants continued their DMARD treatment throughout the 24-week study period.
Receives: Drug: etanercept; Drug: DMARD Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12

    Low disease activity is defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) of less than 3.2. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables: • The number of swollen and tender joints assessed using the 28-joint count; • C-Reactive Protein (CRP) level • Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity).

    The DAS28 score ranges from zero up to approximately ten. DAS28 scores above 5.1 indicate high disease activity.

    Measured: Week 12

Secondary outcomes (41)
  1. Percentage of Participants Achieving DAS28 Remission at Week 12

    Remission is defined by a DAS28 score less than 2.6. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:

    • The number of swollen and tender joints assessed using the 28-joint count;
    • C-reactive protein (CRP)
    • Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity).

    The DAS28 score ranges from zero to ten. DAS28 above 5.1 indicates high disease activity.

    Measured: Week 12

  2. Percentage of Participants Achieving DAS28 Low Disease Activity at All Other Timepoints

    Low disease activity is defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) of less than 3.2. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:

    • The number of swollen and tender joints assessed using the 28-joint count;
    • C-Reactive Protein (CRP) level
    • Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity).

    The DAS28 score ranges from zero up to approximately ten. DAS28 scores above 5.1 indicate high disease activity.

    Measured: Baseline and Weeks 2, 4, 8, 16, 20 and 24

  3. Percentage of Participants Achieving DAS28 Remission at All Other Timepoints

    Remission is defined by a DAS28 score less than 2.6. The DAS28 is a composite score to measure disease activity in patients with rheumatoid arthritis, derived from the following variables:

    • The number of swollen and tender joints assessed using the 28-joint count;
    • C-reactive protein (CRP)
    • Patient's global assessment of disease activity measured on a likert scale from 0 (no activity at all) to 10 (worst activity).

    The DAS28 score ranges from zero to ten. A DAS28 above 5.1 indicates high disease activity.

    Measured: Baseline and Weeks 2, 4, 8, 16, 20 and 24

  4. Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Each Timepoint

    A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in tender joint count; • ≥ 20% improvement in swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: ◦ Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]); ◦ Patient's global assessment of disease activity (measured on a likert scale from 0 to 10); ◦ Physician's global assessment of disease activity (measured on a likert scale from 0 to 10); ◦ Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]); ◦ C-Reactive Protein level.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  5. Percentage of Participants With American College of Rheumatology (ACR) 50 Response at Each Timepoint

    A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 50% improvement in tender joint count;
    • ≥ 50% improvement in swollen joint count; and
    • ≥ 50% improvement in at least 3 of the 5 following parameters:
    • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
    • Patient's global assessment of disease activity (measured on a likert scale from 0 to 10);
    • Physician's global assessment of disease activity (measured on a likert scale from 0 to 10);
    • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
    • C-reactive protein (CRP) level.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  6. Percentage of Participants With American College of Rheumatology (ACR) 70 Response at Each Timepoint

    A participant was a responder if the following 3 criteria for improvement from Baseline were met:

    • ≥ 70% improvement in tender joint count;
    • ≥ 70% improvement in swollen joint count; and
    • ≥ 70% improvement in at least 3 of the 5 following parameters:
    • Patient's assessment of pain (measured on a 100 mm visual analog scale [VAS]);
    • Patient's global assessment of disease activity (measured on a likert scale from 0 to 10);
    • Physician's global assessment of disease activity (measured on a likert scale from 0 to 10);
    • Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index [HAQ-DI]);
    • C-reactive protein (CRP) level.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  7. Percentage of Participants With RAPID3 Remission or Low Severity at Each Time Point

    The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) is adapted from the standard HAQ and is used for the computation of the Routine Assessment of Patient Index Data 3 (RAPID3). The RAPID 3 includes the 3 Core Data Set measures of physical function, pain, and patient global estimate. The score for physical function ranges from 0 to 10 and is calculated by adding the ten activities of daily living, each scored from 0 to 3 by the patient (0="without any difficulty", 1="with some difficulty", 2="with much difficulty", and 3="unable to do") and dividing the total raw score by 3. Pain and global estimate of health are measured on a likert scale from 0 to 10, both scored 0 (best) to 10 (worst). The three 0-10 scores for physical function, pain, and global assesment of health are added together for a composite score of 0 to 30. The RAPID3 composite score includes 4 categories: High Severity > 12, Moderate Severity = 6.1 - 12, Low severity = 3.1 - 6, and Remission ≤ 3.

    Measured: Baseline and Weeks 4, 12, and 24

  8. Percentage of Participants Achieving Count Remission at Each Time Point

    Count remission is achieved when a participant satisfies all of the following at any given time point: - 68 tender joint count ≤ 1, - 66 swollen joint count ≤ 1, - C-reactive protein (CRP) (in mg/dL) ≤1, and - patient global assessment of disease activity ≤ 1 (measured on a likert scale from 0 to 10 ranging from "no activity at all" to "worst activity imaginable").

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  9. Percentage of Participants Achieving CDAI Remission at Each Time Point

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:

    • 28 tender joint count (TJC),
    • 28 swollen joint count (SJC),
    • Patient's Global Assessment of Disease Activity measured on a likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest;
    • Physician's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest.

    The CDAI score ranges from 0-76 where lower scores indicate less disease activity. CDAI remission is defined as a score ≤ 2.8.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  10. Percentage of Participants Achieving CDAI Low Disease Activity at Each Time Point

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:

    • 28 tender joint count (TJC),
    • 28 swollen joint count (SJC),
    • Patient's Global Assessment of Disease Activity measured on a Likert scale form 0 to 10, where 0 = lowest disease activity and 10 = highest;
    • Physician's Global Assessment of Disease Activity -measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest. The CDAI score ranges from 0 to 76 where lower scores indicate less disease activity. CDAI low disease activity is defined as a score ≤ 10.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  11. Clinical Disease Activity Index (CDAI) Score at Each Time Point

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the:

    • 28 tender joint count (TJC),
    • 28 swollen joint count (SJC),
    • Patient's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10 where 0 = lowest disease activity and 10 = highest;
    • Physician's Global Assessment of Disease Activity (measured on a Likert scale from 0 to 10 where 0 = lowest disease activity and 10 = highest).

    The CDAI score ranges from 0 to 76 where lower scores indicate less disease activity.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  12. Percentage of Participants Achieving SDAI Remission at Each Time Point

    The simplified disease activity index (SDAI) is a composite measure that sums the total number of:

    • 28 tender joint counts,
    • 28 swollen joint counts,
    • Patient's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10 where 0= lowest disease activity and 10 = highest;
    • Physician's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest, and
    • C-reactive protein (CRP) in mg/dL.

    The SDAI score ranges from 0 to approximately 86 where lower scores indicate less disease activity. SDAI remission is defined as a score ≤ 3.3.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  13. Percentage of Participants Achieving SDAI Low Disease Activity at Each Time Point

    The simplified disease activity index (SDAI) is a composite measure that sums the total number of: - 28 tender joint counts, - 28 swollen joint counts, - Patient's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10 where 0 = lowest disease activity and 10 = highest; - Physician's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10 where 0 = lowest disease activity and 10 = highest, and - C-reactive protein (CRP) in mg/dL. The SDAI score ranges from 0 to approximately 86 where lower scores indicate less disease activity. SDAI low disease activity is defined as a score ≤ 11.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  14. Simplified Clinical Disease Activity Index (SDAI) Score at Each Time Point

    The simplified disease activity index (SDAI) is a composite measure that sums the total number of:

    • 28 tender joint counts,
    • 28 swollen joint counts,
    • Patient's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest;
    • Physician's Global Assessment of Disease Activity measured on a Likert scale from 0 to 10, where 0 = lowest disease activity and 10 = highest, and
    • C-reactive protein (CRP) in mg/dL.

    The SDAI score ranges from 0 to approximately 86 where lower scores indicate less disease activity.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  15. Tender 28-Joint Count (TJC28) at Each Time Point

    Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  16. Swollen 28-Joint Count (SJC28) at Each Time Point

    Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  17. Patient Global Assessment of Joint Pain at Each Time Point

    The severity of the participant's joint pain was assessed using a visual analog scale (VAS). The participant was asked to draw a mark through a 100 mm horizontal line to indicate how much pain they were experiencing "today", from '0' (no pain at all) on the left end of the line to 100 (worst pain imaginable) on the right end of the line.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  18. Patient's Global Assessment of Disease Activity at Each Time Point

    The participant's global assessment of their arthritis disease activity was assessed by the participant circling a number from 0 to 10 on a horizontal Likert scale ranging from "No Activity at All" (score = 0) to "Worst Activity Imaginable" (score = 10).

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  19. Physician Global Assessment of Disease Activity at Each Time Point

    The global assessment of the participant's arthritis was assessed by the physician circling a number from 0 to 10 on a horizontal Likert scale ranging from "No Activity at All" (score = 0) to "Worst Activity Imaginable" (score = 10).

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  20. Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ-DI) at Each Time Point

    The HAQ-DI asks about the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores). Responses in each functional area are scored from 0 indicating no difficulty to 3 indicating inability to perform a task in that area. The overall score is the average of each of the 8 category scores and ranges from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  21. C-reactive Protein Levels at Each Time Point

    C-Reactive Protein (CRP) was measured from blood samples by a central laboratory as a marker for inflammation.

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  22. Short Form 36 Health Survey (SF-36) Physical Functioning Domain Score at Each Time Point

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. The physical functioning subscale assesses limitations in physical activities because of health problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  23. Short Form 36 Health Survey (SF-36) Vitality Domain Score at Each Time Point

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. The vitality sub-score assesses energy and fatigue. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  24. Short Form 36 Health Survey (SF-36) Role-Physical Domain Score at Each Time Point

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. The role-physical subscale assesses limitations in usual role activities because of physical health problems. Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  25. Short Form 36 Health Survey (SF-36) Bodily Pain Domain Score at Each Time Point

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning (less pain). Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  26. Short Form 36 Health Survey (SF-36) General Health Perceptions Domain Score at Each Time Point

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better quality of life. Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  27. Short Form 36 Health Survey (SF-36) Social Functioning Domain Score at Each Time Point

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning. The social functioning subscale assesses limitations in social activities because of physical or emotional problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  28. Short Form 36 Health Survey (SF-36) Role-Emotional Domain Score at Each Time Point

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better quality of life. The role-emotional subscale assesses limitations in usual role activities because of emotional problems. Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  29. Short Form 36 Health Survey (SF-36) Mental Health Domain Score at Each Time Point

    The SF-36 measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better quality of life. The mental health sub-score assesses general mental health (psychological distress and well-being). Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  30. Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Work Time Missed (Absenteeism) at Each Time Point

    This self-administered questionnaire is designed to address impairment to the work productivity and activity of participants due to rheumatoid arthritis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to rheumatoid arthritis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed. Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  31. Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Impairment While Working (Presenteeism) at Each Time Point

    This self-administered questionnaire is designed to address impairment to the work productivity and activity of participants due to rheumatoid arthritis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which rheumatoid arthritis affected their productivity while working. A higher percentage indicates greater impairment and less productivity. Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  32. Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Activity Impairment at Each Time Point

    This self-administered questionnaire is designed to address impairment to the work productivity and activity of participants due to rheumatoid arthritis. Percent activity impairment is derived from the patient's assessment of the degree to which rheumatoid arthritis affected their regular daily activities. A higher percentage indicates greater impairment and less productivity. Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  33. Work Productivity and Activity Impairment Questionnaire (WPAI): Percent Overall Work Impairment at Each Time Point

    This self-administered questionnaire is designed to address impairment to the work productivity and activity of participants due to rheumatoid arthritis in the past 7 days. Percent overall work impairment takes into account both hours missed due to rheumatoid arthritis symptoms and the participant's assessment of the degree to which rheumatoid arthritis affected their productivity while working. A higher percentage indicates greater impairment and less productivity. Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  34. Participant Assessment of Fatigue at Each Time Point

    The participant's assessment of fatigue was collected using a single-item 100 mm visual analogue scale. The participant was asked to draw a vertical line through a horizontal line to indicate the degree of fatigue they experienced because of their condition over the past week. The horizontal line is 100 mm in length with '0' and 'no fatigue' on the left end of the line and '100' and 'extreme fatigue' on the right end of the line. Least squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 2, 4, 8, 12, 16, 20 and 24

  35. Medical Outcomes Study (MOS) Sleep Disturbance Scale at Each Time Point

    The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Shortness of Breath (1 item). Sleep Disturbance measures the ability to fall asleep and to maintain restful sleep. In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  36. Medical Outcomes Study (MOS) Sleep Shortness of Breath or Headache Scale at Each Time Point

    The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  37. Medical Outcomes Study (MOS) Sleep Snoring Scale at Each Time Point

    The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Shortness of Breath (1 item). In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  38. Medical Outcomes Study (MOS) Sleep Adequacy Scale at Each Time Point

    The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). Sleep Adequacy measures sleep sufficiency in terms of whether the participant sleeps enough to provide restoration of wakefulness. In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. For sleep adequacy a higher score indicates better sleep quality. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  39. Medical Outcomes Study (MOS) Sleep Daytime Somnolence Scale at Each Time Point

    The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). Daytime somnolence measures drowsiness or sleepiness during the day. In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  40. Medical Outcomes Study (MOS) Sleep Problems Index I at Each Time Point

    The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). The scale also produces two indices. The Sleep Problems Index-I is drawn from 6 items in the four domains including Sleep Disturbance (2 items), Sleep Adequacy (2 items), Shortness of Breath (1 item), and Daytime Somnolence (1 item). In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

  41. Medical Outcomes Study (MOS) Sleep Problems Index II at Each Time Point

    The MOS-Sleep comprises 12 items and measures key sleep structures across 6 domains. These domains are Sleep Disturbance (4 items), Sleep Adequacy (2 items), Sleep Quantity (1 item), Daytime Somnolence (3 items), Snoring (1 item), and Awakening short of breath or with a headache, (1 item). The scale also produces two indices. Index-II uses 9 items from four domains including Sleep Disturbance (4 items), Sleep Adequacy (2 items), Shortness of Breath (1 item), and Daytime Somnolence (2 items). In MOS Sleep norm-based scoring, all scales are scored on the same metric, where 50 is the mean for the general U.S. population and 10 is the standard deviation. Higher scores indicate more severe sleep problems. Least Squares means are from a mixed-effect model for repeated measurements (MMRM).

    Measured: Baseline and Weeks 4, 12 and 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Mar 2011 (estimated)
  2. Study startMar 2011
  3. Primary completionFeb 2013
  4. Study completionMay 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
210 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01313208
Sponsor's protocol ID
20070561
Status last verified
Feb 2017
First submitted
10 Mar 2011
Last updated
9 Feb 2017
Data monitoring committee
No

Publications

  • Hobbs K, Deodhar A, Wang B, Bitman B, Nussbaum J, Chung J, Collier DH. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy. Springerplus. 2015 Mar 5;4:113. doi: 10.1186/s40064-015-0895-9. eCollection 2015.

    PubMed 25793152

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing etanercept and DMARD Therapy in people with Rheumatoid Arthritis, run by Amgen at 47 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 47 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Jun 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01313208, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in